Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Shockwave Medical, now a part of Johnson & Johnson MedTech, has consistently been found safe for patients. However, many previous clinical trials excluded high-risk patients, making it important to track real-world outcomes as time goes on.
Toby Rogers, MD, PhD, noted that BASILICA is a fairly complex procedure. Using this advanced technology, however, could make it easier to perform and improve patient access.
New findings have the potential to significantly benefit the field of neuroscience and could help guide researchers in designing more cost-effective, fruitful studies of the brain.
Are care teams doing enough to take on inflammation? The American Heart Association hopes this new research initiative can help answer that question, and many others.
Former ACC president Kim Allan Williams Sr., MD, thinks cardiologists should be much more proactive. Encouraging healthy eating habits now, for example, can keep patients out of the hospital later in life and reduce healthcare spending.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
![The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.](/sites/default/files/styles/240x220/public/2024-12/screenshot_2024-12-02_at_11.07.21_am.png.webp?itok=d6Myns-z)
